Skip to main content
Lifecare ASA logo

Lifecare ASA — Investor Relations & Filings

Ticker · LIFE ISIN · NO0013355859 LEI · 254900D88MYGZ7JD5P39 OL Manufacturing
Open in API
Filings indexed 809 across all filing types
Latest filing 2024-10-10 Director's Dealing
Country NO Norway
Listing OL LIFE

About Lifecare ASA

https://lifecare.no/

Lifecare ASA is a clinical-stage medical sensor company specializing in the development of nanotechnology for medical applications. Its core activity involves creating miniaturized, implantable, and long-term nanobiosensors for the continuous monitoring of various body analytes. The company's primary focus is on developing a sensor for correct and continuous glucose monitoring to improve diabetes management. The business model is based on developing and licensing its proprietary sensor technology to facilitate the production and sale of advanced medical devices.

Recent filings

Filing Released Lang Actions
Lifecare ASA: Mandatory notification of trade
Director's Dealing Classification · 1% confidence The document is titled "Lifecare ASA: Mandatory notification of trade" and explicitly states that a company closely associated with a board member (Hans Hekland) has applied for shares in a public offering. It also mentions attaching a PDMR-form (Persons Discharging Managerial Responsibilities). This type of notification regarding personal share transactions by directors/executives falls directly under the definition of Director's Dealing (DIRS). Although it relates to a capital event (share offering), the core purpose of this specific announcement is reporting the insider's trade/application.
2024-10-10 English
LIFE Study protocol has been finalized for submission to regulatory authorities
Regulatory Filings Classification · 1% confidence The document is a short press release dated October 10, 2024, announcing that the LIFE study protocol has been finalized for submission to regulatory authorities. It references previous reports (Q2 report) and discusses future regulatory steps (CE study submission). Since the document is short (under 5,000 characters) and serves as an announcement about progress towards regulatory compliance and future filings, rather than being a comprehensive financial report (like 10-K or IR) or a transcript, it fits best as a general regulatory announcement or a specific update that doesn't match the other categories precisely. Given the nature of the announcement (progress update on clinical/regulatory path), and the lack of specific financial results or shareholder actions, it is most appropriately classified as a Regulatory Filing (RNS) as a general announcement, or potentially a Legal Proceedings Report (LTR) if the regulatory submission process is viewed as a formal legal/regulatory step, but RNS is the broader fallback for non-standard announcements. Since it is a press release announcing a step in the regulatory process, RNS is the most suitable general category.
2024-10-10 English
LIFE Study protocol has been finalized for submission to regulatory authorities
Regulatory Filings Classification · 1% confidence The document is a press release dated October 10, 2024, announcing that the LIFE Study protocol has been finalized for submission to regulatory authorities concerning their Continuous Glucose Monitor (CGM) development. It discusses progress plans, regulatory compliance, and future steps involving engaging a Contract Researcher Organization (CRO). This type of announcement, detailing progress toward regulatory approval or clinical trials without being a full financial report, an earnings release, or a specific insider transaction, fits best under general regulatory or corporate updates. Since it is an announcement about a step in the regulatory/clinical process, and not a formal filing like a 10-K or an ER, it is best classified as a general Regulatory Filing (RNS) as it is a public disclosure of a material corporate event that doesn't fit the other specific categories (like DIV, DIRS, or CAP). Given the short length and announcement nature, RNS is the most appropriate fallback.
2024-10-10 English
LIFE Longevity trial: Biopsy and bacteriological examination confirm no unexpected foreign body reactions after removal of implant
Regulatory Filings Classification · 1% confidence The document is a press release from Lifecare ASA detailing the results of a longevity trial for their medical sensor, specifically confirming the absence of adverse foreign body reactions based on biopsy and bacteriological tests after implant removal. This is an announcement of clinical/study results and operational updates, not a formal regulatory filing like a 10-K, a comprehensive quarterly report (IR), or a standard earnings release (ER). It discusses scientific findings and progress in a clinical trial. Since it is a specific announcement of study results and operational progress that doesn't fit the defined categories like 'Audit Report' (AR) or 'Earnings Release' (ER), it falls best under the general 'Regulatory Filings' (RNS) category as a miscellaneous regulatory/operational announcement, or potentially 'LTR' if the trial results were mandated by a regulator, but RNS is the safer general announcement fallback.
2024-10-08 English
LIFE Longevity trial: Biopsy and bacteriological examination confirm no unexpected foreign body reactions after removal of implant
Regulatory Filings Classification · 1% confidence The document is a press release dated October 8, 2024, from Lifecare ASA detailing the results of biopsy and bacteriological examinations following the removal of an implant from their longevity trial. It discusses trial progress, safety findings (no foreign body reactions, no adverse effects), and future testing plans. This type of announcement, focusing on clinical trial results and safety data, does not fit neatly into the specific categories like 10-K, ER, or IR. It is a general update on scientific/clinical progress. Since it is not a formal regulatory filing (like a 10-K or IR) but rather a specific announcement of scientific findings, the most appropriate general category is Regulatory Filings (RNS) as a fallback for miscellaneous corporate/scientific updates that don't match the other specific types, although it could also be argued as a type of Investor Presentation (IP) if it were a slide deck, but as a press release detailing results, RNS is the best fit among the provided options for non-standard, non-financial periodic reports.
2024-10-08 English
Lifecare ASA: Launch of public retail offering and commencement of application period
Capital/Financing Update Classification · 1% confidence The document is titled "LIFECARE ASA: LAUNCH OF PUBLIC RETAIL OFFERING AND COMMENCEMENT OF APPLICATION PERIOD". It details the terms of an offering of new shares (up to 1,000,000 Offer Shares) for gross proceeds up to NOK 20 million, specifying the offer price, application period, and use of proceeds (R&D and investments). This clearly describes a capital raising or financing activity. This aligns directly with the definition for Capital/Financing Update (CAP). Although it mentions a Prospectus, the document itself is the announcement detailing the offering terms, not the Prospectus or a general report publication announcement (RPA), as it contains substantive details about the financing event itself.
2024-10-08 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.